Introduction
Signal transducer and activator of transcription 3 (Stat3) is involved in a wide variety of cellular functions, and Stat 3 has been found to be constitutively activated (tyrosine phosphorylation/nuclear localization) in a wide spectrum of human malignancies of both epithelial and hematopoietic origins (Bowman et al., 2000; Bromberg, 2002; Levy and Darnell, 2002) . Recently, we found that Stat3 is rapidly activated in mouse epidermis following topical treatment with diverse tumor promoters, including 12-O-tetradecanoylphorbol-13-acetate (TPA), okadaic acid and chrysarobin (Chan et al., 2004a) . Furthermore, we found that mice with Stat3 function disrupted in keratinocytes were highly resistant to two-stage carcinogenesis (Chan et al., 2004b) . We further demonstrated that Stat3 plays distinct roles in both the initiation and promotion stages of carcinogenesis, respectively, by maintaining survival of DNA-damaged stem cells and by mediating proliferation necessary for the clonal expansion of initiated cells (Chan et al., 2004b) . Finally, inhibition of Stat3 function via intra-tumoral injection of a decoy oligonucleotide led to significant reduction in size of papillomas in approximately 50% of all tumors tested. Bromberg et al. (1999) previously reported the characterization of a constitutively dimerized (activated) form of Stat3 (Stat3C) produced via substitution of amino acid residues 661 and 663 near the C terminus with cysteine. Stat3C monomers form disulfide bonds with each other, leading to constitutive dimerization without the requirement for tyrosine phosphorylation (Bromberg et al., 1999) . Stat3C was able to transform mouse and rat fibroblasts as demonstrated by anchorageindependent growth of transfected cells in soft agar and Stat3C-transfected fibroblasts injected into nude mice were tumorigenic (Bromberg et al., 1999) . These and other data have led to the hypothesis that Stat3 can act, under certain conditions, as an oncogene.
In the current study, we have explored the functional consequences of elevated Stat3 activity on development of skin tumors in vivo using a transgenic mouse model in which Stat3C expression is targeted to the proliferative compartment of epidermis via the bovine keratin 5 promoter (K5.Stat3C mice). The K5.Stat3C mice develop hyperproliferative skin lesions resembling human psoriasis in response to wounding or TPA treatment (Sano et al., 2005) , suggesting that K5.Stat3C mice may have altered sensitivity to a two-stage skin carcinogenesis regimen. The results of the present study confirm an important role for Stat3 in the early stages of epithelial carcinogenesis and reveal a novel role in malignant progression of skin tumors in this model system.
Results

Stat3C expression protects keratinocytes from DMBA-induced apoptosis
To explore the impact of Stat3C expression on keratinocyte survival during initiation, transgenic mice were treated topically with either 25, 100 or 1000 nmol of 7,12-dimethylbenz[a]anthracene (DMBA). As shown in Figure 1 , the number of apoptotic keratinocytes (caspase-3-positive cells/cm) was significantly (Pp0.05) reduced in the epidermis of K5.Stat3C mice at each dose of DMBA.
Stat3C expression sensitizes keratinocytes to TPA-induced epidermal hyperproliferation After four topical treatments of TPA, basal keratinocytes of K5.Stat3C mice had a greater elevation in labeling index (LI) compared to control mice, as shown by the increase in BrdU-labeled cells, which was dosedependent ( Figure 2a) . Furthermore, following a single treatment of TPA, there was a significantly enhanced peak in the LI at B17 h and a prolonged and elevated LI throughout the remaining time course in epidermis of K5.Stat3C mice compared to non-transgenic mice (Figure 2b ). Western blot analysis of epidermal lysates revealed a higher basal level of cyclin D1 in K5.Stat3C mice, which was sustained in response to TPA treatment throughout the time course experiment (Figure 2c ).
Stat3C expression sensitizes epidermis to two-stage carcinogenesis As shown in Figure 3 , K5.Stat3C transgenic mice developed skin tumors with a shorter latency (Figure 3a) and at a significantly higher number (Figure 3b ) when compared to non-transgenic littermates. Spontaneous skin tumors were not observed in untreated K5.Stat3C mice even at >1.5 years of age (n ¼ 15). The skin tumors that developed in K5.Stat3C transgenic mice arose as flat lesions lacking the characteristic raised and pedunculated appearance of the typical exophytic papillomas that develop in non-transgenic mice (Figures 4a and d , respectively). Histopathologic evaluation of these skin tumors revealed that as early as 6 weeks of promotion they could be classified as carcinoma in situ with microinvasion into the surrounding dermal/mesenchymal tissues. By the end of the experiment (22 weeks of Figure 4c . Notably, within the relatively short-time frame of this regimen, one case of lung metastasis was observed in a transgenic mouse (Figure 4f ). DNA sequencing analysis of the skin tumors from Stat3C transgenic mice showed that 75% (12/16) carried an activating Ha-ras mutation, the majority of which were A 182 -T transversions in codon 61 (data not shown). Finally, treatment of K5.Stat3C transgenic mice and non-transgenic littermates with either a single treatment of DMBA (n ¼ 12) or repetitive treatment with TPA (n ¼ 12) did not give rise to tumor development after 30 weeks (data not shown).
Stat3C expressing tumors display enhanced angiogenesis, and early loss of differentiation markers After topical treatment with TPA, there was a significant increase in the number of blood vessels, as determined by quantitation of CD31 positive cells, in the dermis of K5.Stat3C mice compared to non-transgenic littermates ( Figure 5a ). Blood vessel networks associated with SCCs from K5.Stat3C transgenic mice were more highly developed than the typical, but clearly less extensive, blood vessel network associated with SCCs of similar size in non-transgenic mice (Figure 5b ). Staining for CD31 is also shown for both tumors. As shown in Figure 6a , K10 and filaggrin expression was relatively intact in papillomas obtained from nontransgenic mice at 20 weeks of promotion. In contrast, partial loss of K10 and filaggrin expression could be seen in skin tumors from transgenic mice by 10 weeks and essentially complete loss of these two differentiation markers was observed in skin tumors by 20 weeks of promotion. In fact, focal loss of K10 was apparent in the epidermis of transgenic mice before tumor development (see Supplementary data). The loss of both K10 and filaggrin correlated with the severity of the lesions.
As shown in Figure 6a , papillomas from nontransgenic mice also showed intact E-cadherin expression in the intercellular junctions of tumor cells. In contrast, partial loss of E-cadherin expression was observed in tumors from K5.Stat3C transgenic mice as early as 10 weeks and by 20 weeks E-cadherin expression was markedly decreased. In transgenic mice, tumor cells with complete loss of E-cadherin expression correlated with a less-differentiated morphology. Finally, an approximately 2-fold increase in Twist expression was observed in skin tumors from BK5.Stat3C mice at a time when E-cadherin expression was significantly reduced (Figure 6b ).
Expression of Stat3C in 3PC cells enhances tumor cell migration and invasion
The keratinocyte cell line, 3PC (Miller et al., 1987) , was stably transfected with different levels of a Stat3C expression vector (3PC-1, 3PC-8 and 3PC-10) and the elevation of Stat3 protein expression was verified by both western blot analysis (data not shown) and immunohistochemical staining for the Stat3C flag-tag. The cell line with the highest expression of the Stat3C vector (3PC-10) was selected to explore the functional consequences of elevated Stat3 activity in tumor cell migration and invasion. When cultured in standard medium without growth factor stimulation, Stat3C overexpression led to a statistically significant enhancement in 3PC cell migration and invasion through Matrigel (Supplementary Figure 2) . Notably, after stimulation with either EGF or HGF, 3PC-10 cells exhibited a further, significant enhancement in both cell migratory and invasive properties (Supplementary Figure 2) that was statistically different from control keratinocytes.
Discussion
In the present study, we demonstrate that expression of a constitutively active/dimerized form of Stat3 in the Stat3 in malignant progression of skin tumors KS Chan et al basal compartment of mouse epidermis leads to a dramatic effect on the development and progression of skin tumors. In this regard, using a standard twostage, chemical carcinogenesis regimen, K5.Stat3C mice developed skin tumors with shortened latency and greater number compared to non-transgenic littermates (Figure 3) . Furthermore, 100% of the skin tumors that developed in K5.Stat3C transgenic mice were initially diagnosed as carcinoma in situ and these tumors exhibited invasion into surrounding mesenchymal tissue at a very early stage (Figure 4) . Most of these lesions progressed rapidly to SCCs, and were highly vascularized and poorly differentiated (see Figures 4-6) . Overall, these data confirm that Stat3 plays an important role during both the initiation and promotion stages of carcinogenesis and reveal a novel role for Stat3 in driving malignant progression in this established model of epithelial multistage carcinogenesis.
In our previous studies, we reported that the resistance of Stat3 deficient mice to epidermal two-stage carcinogenesis was attributed to both an increase in apoptosis of DNA-damaged keratinocyte stem cells during initiation with DMBA and a reduced proliferative response following topical treatment with TPA (Chan et al., 2004b) . The reduced proliferative response was found to be due to a delayed G1 to S-phase transition, and reduced levels of cyclin D1, cyclin E and c-myc in epidermis of Stat3 deficient mice contributed to this effect. Keratinocytes from K5.Stat3C transgenic mice were resistant to DMBA-induced apoptosis at initiating doses in the range of 25-1000 nmol and hypersensitive to the proliferative effects of TPA. The elevation of the basal level of cyclin D1 protein in untreated epidermis of K5.Stat3C transgenic mice as well as the greater increase after TPA treatment likely contributed to enhancement of TPA-induced hyperproliferation and the rapid development of skin tumors during tumor promotion. Robles et al. (1998) have shown that cyclin D1 knockout mice are highly resistant to two-stage skin carcinogenesis indicating an important role for cyclin D1 in ras-mediated skin tumor development. In addition, there was a significant increase in blood vessel development in the skin of K5.Stat3C mice following TPA treatment ( Figure 5) . Larcher et al. (1998) reported that overexpression of VEGF in epidermis of transgenic mice using the K6 promoter led to enhanced formation of papillomas, although no increase in malignant progression was observed. Therefore, elevated VEGF and increased vascularization together with elevated cyclin D1, and possibly other cell cycle regulatory proteins (for example, c-Myc and cyclin E) during tumor promotion likely contributed to the rapid development and progression of skin tumors in K5.Stat3C mice.
An unexpected observation in the current study was that expression of constitutively active Stat3 in keratinocytes led to a very rapid progression of skin tumors. The early loss of K10 and filaggrin expression and loss of E-cadherin expression are consistent with the very rapid progression of skin tumors in K5.Stat3C mice. Keratin 10 and filaggrin are well-established markers of keratinocyte differentiation (Fuchs, 1994; Yuspa, 1994) and loss of E-cadherin is considered a marker of epithelial-mesenchymal transition (EMT) (Kalluri and Neilson, 2003; Thiery, 2003; Kang and Massague, 2004) as well as a marker for progression of skin tumors in mice (Navarro et al., 1991; Ruggeri et al., 1992; Cano et al., 1996; Faraldo et al., 1997) .
Recent evidence suggests that Stat3 may regulate genes involved in EMT in several species (Yamashita et al., 2004) . In addition to the early loss of E-cadherin, we found that Twist protein levels were B2-fold higher Twist is a transcription factor that has been implicated in EMT through repression of E-cadherin expression (Kang and Massague, 2004; Yang et al., 2006) . Recent results suggest that Stat3 may regulate Twist expression (Ling and Arlinghaus, 2005) . Thus, overexpression of Stat3C either directly and/or indirectly may have facilitated EMT and tumor progression through regulation of Twist and E-cadherin expression. Because the current study was terminated at 22 weeks of promotion, none of the tumors in K5.Stat3C mice had progressed to spindle cell carcinomas. This is supported by the fact that the transgene (driven by the K5 promoter) was still expressed in the tumors. Thus, further work will be necessary to determine the overall effect of elevated Stat3 activity on EMT in this model system. Recent studies have also shown that Stat3 can regulate expression of genes involved in invasion and metastasis (Dauer et al., 2005; Kortylewski et al., 2005) . Expression of phosphorylated Stat3 in non-melanoma skin cancers was higher in poorly differentiated SCCs and also correlated with both the depth of tumor invasion and with metastasis (Suiqing et al., 2005) . Using a well-established in vitro migration assay, we found a statistically significant increase in the migration properties of a keratinocyte cell line (3PC) following transfection with a Stat3C expression construct (Supplementary Figure 2 ). Migration of these cells was further enhanced after stimulation with EGF or HGF. Furthermore, invasion through Matrigel was also elevated in a similar manner (Supplementary Figure  2) . Many growth factors (for example, EGF receptor ligands) are upregulated during tumor promotion in the mouse skin model (Rho et al., 1994; Kiguchi et al., 1998) . Previous work using a human skin organ culture model demonstrated enhanced invasion of epidermal Stat3 in malignant progression of skin tumors KS Chan et al keratinocytes into the underlying dermal tissue following exposure to both EGF and HGF (Zeigler et al., 1996) . Collectively, our data indicate that elevated Stat3 activity in keratinocytes can stimulate properties associated with tumor invasion and metastasis.
In conclusion, the current study provides new insight into the possible role(s) for Stat3 in epithelial carcinogenesis. In addition to its critical role in both the initiation and promotion stages of epithelial carcinogenesis, we have identified a novel role for Stat3 in driving malignant progression. While the exact mechanism(s) underlying this latter observation remain to be elucidated, several clues arise from the current study. First, enhanced Stat3 activity led to enhancement of angiogenesis providing for rapid development of blood vessel networks. Second, elevated Stat3 activity may regulate expression of genes involved in EMT (for example, Twist, E-cadherin). Finally, papilloma cells expressing Stat3C displayed enhanced migration and invasion in vitro, especially, in response to growth factors (both autocrine and paracrine growth factors). Our results show that Stat3 plays important roles throughout epithelial carcinogenesis making its potential as a target for both prevention and treatment of cancer worthy of continued study. 
Materials and methods
K5.Stat3C transgenic mice and two-stage carcinogenesis protocols K5.Stat3C transgenic mice were generated and characterized as previously described (Sano et al., 2005) . Adult transgenic and non-transgenic littermates were used for the described experiments at 6-8 weeks of age. The dorsal skin of each mouse was shaved 48 h before treatment; only those mice in the resting phase of the hair cycle were utilized. All solutions of DMBA (Sigma-Aldrich, Milwaukee WI, USA) and TPA (LC Laboratories, Woburn MA, USA) were prepared in reagent grade acetone and applied topically in a total volume of 0.2 ml. For the two-stage carcinogenesis experiment, mice were initiated with a single topical application of 25 nmol DMBA. At 2 weeks after initiation, TPA (3.4 nmol) was applied topically twice weekly. Mice were killed and skin tumors were collected as indicated throughout the course of TPA treatment.
Analysis of epidermal apoptosis and epidermal LI Groups of mice (n ¼ 3) were used for all treatment groups. For determination of apoptosis, mice were treated with DMBA (25, 100 or 1000 nmol) or acetone (0.2 ml) on the dorsal skin and were killed 24 h after treatment. Skin sections were stained with an antibody to the active form of caspase-3 (R and D Systems Inc., Minneapolis, MN, USA) and apoptotic keratinocytes determined as previously described (Chan et al., 2004b) . For the analysis of epidermal LI, mice were treated with either a single application of TPA (6.8 nmol) or acetone and killed at various times after treatment. The LI was determined as described (Chan et al., 2004b) .
Preparation of protein lysates and western blot analysis
Preparation of epidermal lysates, electrophoresis and protein detection were previously described (Chan et al., 2004b) . Specific primary antibodies used were as follows: Stat3 (C-20, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), phospho-Stat3 (Cell Signaling Technology, Inc., Beverly, MA, USA), cyclin D1 (NeoMarkers, Fremont, CA, USA), anti-flag M-20 (Sigma-Aldrich Co.) and actin (I-19) (Santa Cruz Biotechnology Inc.).
Immunohistochemical analysis
Formalin-fixed, paraffin-embedded tissues were deparaffinized and hydrated using standard procedures. Endogenous peroxidase activity was blocked with 0.03% hydrogen peroxide for 10 min. Sections were microwaved (10 min) in the presence of 10 mM citrate buffer (pH 6.0) containing 0.01% Tween 20 and allowed to cool for 20 min and stained with antibodies against CD 31 (BD BioSciences, Pharmingen, San Jose, CA, USA), K10 and filaggrin (Covance Research Products, Denver, PA, USA)and E-cadherin (Santa Cruz Biotechnology Inc.) following the manufacturer's instructions. The antibody used to detect the flag-tag of the Stat3C protein was purchased from Sigma-Aldrich (St Louis, MO, USA).
Ha-ras mutation screen and sequence analysis The initial screen for gene mutations of Ha-ras at codon 61 was performed as described previously (Tang et al., 2000) . DNA samples identified with mutations by this method, which couples PCR amplification with restriction enzyme digest analysis were then amplified directly from genomic DNA and sequenced.
